Drug Manufacturers - Specialty & Generic
Compare Stocks
3 / 10Stock Comparison
PTPI vs PRGO vs HIMS
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Medical - Equipment & Services
PTPI vs PRGO vs HIMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Medical - Equipment & Services |
| Market Cap | $56K | $1.62B | $7.30B |
| Revenue (TTM) | $725K | $4.18B | $2.35B |
| Net Income (TTM) | $-7M | $-1.82B | $128M |
| Gross Margin | 63.5% | 34.2% | 69.7% |
| Operating Margin | -18.4% | -4.1% | 4.6% |
| Forward P/E | — | 5.5x | 58.3x |
| Total Debt | $7M | $3.97B | $1.12B |
| Cash & Equiv. | $4M | $532M | $229M |
PTPI vs PRGO vs HIMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Petros Pharmaceutic… (PTPI) | 100 | 0.0 | -100.0% |
| Perrigo Company plc (PRGO) | 100 | 26.2 | -73.8% |
| Hims & Hers Health,… (HIMS) | 100 | 193.6 | +93.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PTPI vs PRGO vs HIMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PTPI is the clearest fit if your priority is dividends.
- 100.0% yield, 1-year raise streak, vs PRGO's 9.8%, (1 stock pays no dividend)
PRGO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 10 yrs, beta 1.21, yield 9.8%
- Lower volatility, beta 1.21, current ratio 2.76x
- Beta 1.21, yield 9.8%, current ratio 2.76x
HIMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 188.5% 10Y total return vs PRGO's -77.7%
- 59.0% revenue growth vs PTPI's -12.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs PTPI's -12.2% | |
| Value | Lower P/E (5.5x vs 58.3x) | |
| Quality / Margins | 5.5% margin vs PTPI's -9.7% | |
| Stability / Safety | Beta 1.21 vs HIMS's 2.48, lower leverage | |
| Dividends | 100.0% yield, 1-year raise streak, vs PRGO's 9.8%, (1 stock pays no dividend) | |
| Momentum (1Y) | -45.0% vs PTPI's -94.4% | |
| Efficiency (ROA) | 6.0% ROA vs PTPI's -114.5%, ROIC 10.7% vs -7.3% |
PTPI vs PRGO vs HIMS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
PTPI vs PRGO vs HIMS — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HIMS leads in 3 of 6 categories
PRGO leads 2 • PTPI leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 5760.1x PTPI's $725,403. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to PTPI's -9.7%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $725,403 | $4.2B | $2.3B |
| EBITDAEarnings before interest/tax | -$12M | $58M | $164M |
| Net IncomeAfter-tax profit | -$7M | -$1.8B | $128M |
| Free Cash FlowCash after capex | -$5M | $108M | $73M |
| Gross MarginGross profit ÷ Revenue | +63.5% | +34.2% | +69.7% |
| Operating MarginEBIT ÷ Revenue | -18.4% | -4.1% | +4.6% |
| Net MarginNet income ÷ Revenue | -9.7% | -43.5% | +5.5% |
| FCF MarginFCF ÷ Revenue | -6.7% | +2.6% | +3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -7.2% | +28.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +95.9% | -56.4% | -27.3% |
Valuation Metrics
PRGO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than HIMS's 46.5x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $56,182 | $1.6B | $7.3B |
| Enterprise ValueMkt cap + debt − cash | $4M | $5.1B | $8.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -1.14x | 55.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.53x | 58.29x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.43x | 46.50x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 0.38x | 3.11x |
| Price / BookPrice ÷ Book value/share | — | 0.55x | 13.50x |
| Price / FCFMarket cap ÷ FCF | — | 11.17x | 98.70x |
Profitability & Efficiency
HIMS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-2 for PTPI. PRGO carries lower financial leverage with a 1.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), PRGO scores 4/9 vs PTPI's 3/9, reflecting mixed financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -50.7% | +23.7% |
| ROA (TTM)Return on assets | -114.5% | -19.8% | +6.0% |
| ROICReturn on invested capital | -7.3% | +3.7% | +10.7% |
| ROCEReturn on capital employed | -2.3% | +4.3% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 4 |
| Debt / EquityFinancial leverage | — | 1.35x | 2.07x |
| Net DebtTotal debt minus cash | $4M | $3.4B | $892M |
| Cash & Equiv.Liquid assets | $4M | $532M | $229M |
| Total DebtShort + long-term debt | $7M | $4.0B | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | -79.35x | -7.20x | — |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $27,393 today (with dividends reinvested), compared to $0 for PTPI. Over the past 12 months, HIMS leads with a -45.0% total return vs PTPI's -94.4%. The 3-year compound annual growth rate (CAGR) favors HIMS at 33.6% vs PTPI's -95.9% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -12.5% | -13.6% | -15.4% |
| 1-Year ReturnPast 12 months | -94.4% | -52.0% | -45.0% |
| 3-Year ReturnCumulative with dividends | -100.0% | -58.1% | +138.6% |
| 5-Year ReturnCumulative with dividends | -100.0% | -60.3% | +173.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -77.7% | +188.5% |
| CAGR (3Y)Annualised 3-year return | -95.9% | -25.2% | +33.6% |
Risk & Volatility
PRGO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than HIMS's 2.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRGO currently trades 41.2% from its 52-week high vs PTPI's 3.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.21x | 2.48x |
| 52-Week HighHighest price in past year | $0.21 | $28.44 | $70.43 |
| 52-Week LowLowest price in past year | $0.00 | $9.23 | $13.74 |
| % of 52W HighCurrent price vs 52-week peak | +3.3% | +41.2% | +40.1% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 53.1 | 50.2 |
| Avg Volume (50D)Average daily shares traded | 40K | 3.3M | 34.8M |
Analyst Outlook
Evenly matched — PTPI and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PRGO as "Hold", HIMS as "Hold". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs -7.3% for HIMS (target: $26). For income investors, PTPI offers the higher dividend yield at 100.00% vs PRGO's 9.82%.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold |
| Price TargetConsensus 12-month target | — | $36.20 | $26.20 |
| # AnalystsCovering analysts | — | 36 | 19 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | +9.8% | — |
| Dividend StreakConsecutive years of raises | 1 | 10 | — |
| Dividend / ShareAnnual DPS | $161.09 | $1.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.2% |
HIMS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
PTPI vs PRGO vs HIMS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PTPI or PRGO or HIMS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 55. 4x trailing P/E (58. 3x forward), making it the more compelling value choice. Analysts rate Perrigo Company plc (PRGO) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PTPI or PRGO or HIMS?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PTPI or PRGO or HIMS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +173. 9%, compared to -100. 0% for Petros Pharmaceuticals, Inc. (PTPI). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus PTPI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PTPI or PRGO or HIMS?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
21β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 104% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Perrigo Company plc (PRGO) carries a lower debt/equity ratio of 135% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PTPI or PRGO or HIMS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). On earnings-per-share growth, the picture is similar: Petros Pharmaceuticals, Inc. grew EPS 47. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PTPI or PRGO or HIMS?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus -280. 1% for Petros Pharmaceuticals, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -345. 8% for PTPI. At the gross margin level — before operating expenses — PTPI leads at 76. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PTPI or PRGO or HIMS more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
5x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 52. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.
08Which pays a better dividend — PTPI or PRGO or HIMS?
In this comparison, PTPI (100.
0% yield), PRGO (9. 8% yield) pay a dividend. HIMS does not pay a meaningful dividend and should not be held primarily for income.
09Is PTPI or PRGO or HIMS better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
21), 9. 8% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PTPI and PRGO and HIMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PTPI is a small-cap income-oriented stock; PRGO is a small-cap income-oriented stock; HIMS is a small-cap high-growth stock. PTPI, PRGO pay a dividend while HIMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.